Stay updated with breaking news from Debra Patt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Trial results from DESTINY-Breast06 indicate the effectiveness of fam-trastuzumab deruxtecan-nxki in delaying disease progression for patients with hormone receptor (HR)–positive and HER2-low metastatic breast cancer who had prior endocrine therapy.
More states are barring the practice of white bagging, while oncology groups and insurance advocates continue to debate its impacts on costs.
Our top coverage from this year’s Community Oncology Conference, hosted by the Community Oncology Alliance, included discussions around alternative payment models, shifts in the community oncology landscape in recent decades, and the need for reform in several areas.
In a session held during the 2023 Patient-Centered Oncology Care® meeting, Erin Trish, PhD, co-director of the USC Schaeffer Center, fielded questions about the pharmacy benefit manager (PBM) landscape from Stephen Schleicher, MD, MBA, chief medical officer at Tennessee Oncology.
There is bipartisan support in the Congress for the Community Oncology Alliance's (COA) key agenda items, with hope that some will pass by year’s end.